Lifeward Ltd. (LFWD)
NASDAQ: LFWD · Real-Time Price · USD
1.725
+0.025 (1.47%)
Apr 1, 2025, 10:18 AM EDT - Market open
Lifeward Revenue
In the year 2024, Lifeward had annual revenue of $25.66M with 85.24% growth. Lifeward had revenue of $7.55M in the quarter ending December 31, 2024, with 9.60% growth.
Revenue (ttm)
$25.66M
Revenue Growth
+85.24%
P/S Ratio
0.58
Revenue / Employee
$320,788
Employees
80
Market Cap
18.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 25.66M | 11.81M | 85.24% |
Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
LFWD News
- 19 days ago - FDA Issues Clearance for ReWalk 7 Exoskeleton - GlobeNewsWire
- 24 days ago - Lifeward Ltd. (LFWD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 26 days ago - Lifeward and CorLife Finalize Partnership to Expand Workers' Compensation Access to ReWalk Exoskeleton - GlobeNewsWire
- 27 days ago - Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use - GlobeNewsWire
- 4 weeks ago - Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025 - GlobeNewsWire
- 5 weeks ago - Lifeward Announces CEO Transition - GlobeNewsWire
- 2 months ago - Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities - GlobeNewsWire